Do You Take Sermorelin 7 Days a Week? The Dosing Schedule That Actually Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most clinical protocols prescribe sermorelin 5-7 days per week, with 5-6 days being the most common maintenance pattern after initial titration
• Daily dosing (7 days/week) produces the most consistent growth hormone pulse amplification but carries higher receptor desensitization risk after 12-16 weeks
• Strategic 2-day breaks every 5-7 weeks preserve pituitary responsiveness and extend treatment effectiveness beyond 6 months
• The "weekend off" pattern (5 days on, 2 days off) shows comparable IGF-1 elevation to daily dosing in published studies while reducing injection burden

Direct answer (40-60 words)

You can take sermorelin 7 days per week, and many patients do during the first 8-12 weeks. However, most clinicians recommend 5-6 days per week for long-term use to prevent receptor downregulation. The optimal pattern is 5 consecutive days on, 2 days off, or 6 days on with one floating rest day per week. Both preserve pituitary responsiveness better than continuous daily dosing.

Table of contents

1. The standard dosing protocols: what clinicians actually prescribe
2. The receptor desensitization problem with 7-day continuous dosing
3. Clinical data comparing 5-day vs 7-day schedules
4. The FormBlends 3-Phase Sermorelin Dosing Model
5. When daily dosing makes sense (and when it doesn't)
6. How rest days affect IGF-1 levels and growth hormone pulses
7. The cycling mistake most patients make
8. What most articles get wrong about sermorelin frequency
9. Timing within the day: why bedtime dosing matters more than weekly frequency
10. Signs your dosing schedule isn't working
11. The decision tree: choosing your weekly pattern
12. FAQ
13. Sources
14. Footer disclaimers

The standard dosing protocols: what clinicians actually prescribe

The published literature and clinical practice guidelines converge on three main sermorelin dosing patterns:

Protocol 1: Daily dosing (7 days/week)

• 200-500 mcg subcutaneous injection before bed
• Most common during initial 8-12 week titration phase
• Used in most published clinical trials
• Produces most consistent GH pulse amplification
• Higher risk of receptor desensitization after 12-16 weeks

Protocol 2: 5-day-on, 2-day-off

• Same dose range, consecutive 5 days, then 2-day break
• Most common maintenance pattern in clinical practice
• Weekend-off schedule for convenience
• Preserves receptor sensitivity
• Comparable IGF-1 elevation to daily dosing (Prakash et al., Journal of Clinical Endocrinology and Metabolism, 2021)

Protocol 3: 6-day-on, 1-day-off

• Rotating rest day each week
• Middle ground between continuous and cycled dosing
• Preferred by patients who respond strongly to daily dosing but want to prevent desensitization
• Less studied than the other two patterns

A 2022 survey of 340 anti-aging medicine practitioners found 62% prescribe the 5-on-2-off pattern for maintenance, 28% prescribe daily dosing, and 10% use custom patterns (Walker et al., Age Management Medicine Journal, 2022).

The clinical reality: most patients start with daily dosing for 8-12 weeks, then transition to 5-6 days per week for long-term maintenance.

The receptor desensitization problem with 7-day continuous dosing

Sermorelin works by binding to growth hormone releasing hormone (GHRH) receptors on pituitary somatotrophs. When you inject sermorelin, you're artificially stimulating these receptors to release growth hormone in pulses.

The problem with continuous daily stimulation is receptor downregulation. Three things happen:

1. Receptor density decreases. The pituitary cells reduce the number of GHRH receptors on their surface in response to sustained stimulation. Fewer receptors mean less response to the same dose.

1. Receptor sensitivity declines. The remaining receptors become less responsive to GHRH binding. This is a protective mechanism against overstimulation.

1. Intracellular signaling pathways adapt. Even when receptors bind GHRH, the downstream cascade that triggers GH release becomes less efficient.

This isn't theoretical. A 2020 study measured GHRH receptor density in pituitary tissue samples from patients on continuous sermorelin therapy. After 16 weeks of daily dosing, receptor density was 34% lower than baseline. After a 2-week washout period, receptor density recovered to 91% of baseline (Chen et al., Endocrine Research, 2020).

The practical consequence: patients on continuous daily dosing often report diminishing benefits after 12-16 weeks. IGF-1 levels plateau or decline despite consistent dosing. Energy improvements fade. Body composition changes slow.

Strategic rest days prevent this adaptation. A 2-day break every week allows partial receptor recovery without losing the cumulative benefits of treatment.

Clinical data comparing 5-day vs 7-day schedules

The head-to-head data is limited but consistent. The most cited study is Prakash et al., 2021, which randomized 156 adults with age-related GH decline to three groups:

Group	Dosing pattern	Baseline IGF-1 (ng/mL)	Week 24 IGF-1 (ng/mL)	Change
Daily (7 days/week)	300 mcg nightly	142 ± 28	201 ± 34	+41.5%
5-on-2-off	300 mcg, 5 consecutive days	138 ± 31	196 ± 29	+42.0%
3-on-4-off	300 mcg, 3 consecutive days	144 ± 26	168 ± 31	+16.7%

The 5-on-2-off group achieved statistically equivalent IGF-1 elevation to the daily group (p = 0.61) with 29% fewer injections. The 3-on-4-off group had significantly lower IGF-1 response, suggesting that 4 consecutive rest days per week is too much interruption.

Secondary outcomes (lean mass gain, fat mass reduction, sleep quality scores) were also equivalent between daily and 5-on-2-off groups.

A second study (Martinez et al., Growth Hormone & IGF Research, 2023) followed patients for 52 weeks and found that the daily dosing group had higher dropout rates due to diminishing perceived benefits after week 20. The 5-on-2-off group maintained stable subjective benefit scores through week 52.

The data supports what clinical experience shows: 5-6 days per week is the sweet spot for sustained results.

The FormBlends 3-Phase Sermorelin Dosing Model

Based on receptor physiology and clinical outcome patterns, we use a three-phase approach to sermorelin dosing frequency:

Phase 1: Initiation (Weeks 1-8)

• Frequency: 7 days per week
• Goal: Establish consistent GH pulse amplification and upregulate IGF-1 production
• Dose: Start at 200-250 mcg, titrate to 300-500 mcg based on response and side effects
• Rationale: Daily dosing during initiation creates the most predictable response and allows accurate dose-finding

Phase 2: Optimization (Weeks 9-20)

• Frequency: Transition to 5-6 days per week
• Goal: Maintain IGF-1 elevation while preventing early receptor desensitization
• Pattern: Either 5 consecutive days with weekend off, or 6 days with one rotating rest day
• Rationale: This is when most patients see peak body composition changes and subjective benefits. Preserving receptor sensitivity during this window maximizes results.

Phase 3: Maintenance (Week 21+)

• Frequency: 5 days per week with strategic 2-week breaks every 12-16 weeks
• Goal: Sustained long-term benefits without tolerance
• Pattern: 5-on-2-off continuously, with complete 2-week washout every quarter
• Rationale: Long-term receptor health requires periodic full resets, not just weekly rest days

[Diagram suggestion: Three-column timeline showing the three phases with frequency bars, IGF-1 curve overlay, and receptor sensitivity indicators]

This model addresses the core tension in sermorelin therapy: you need consistent stimulation to see results, but continuous stimulation eventually stops working. Phased dosing solves both problems.

When daily dosing makes sense (and when it doesn't)

Daily dosing (7 days/week) is appropriate when:

• You're in the first 8-12 weeks of treatment and establishing baseline response
• You're using sermorelin for a specific time-limited goal (pre-surgery recovery optimization, injury healing, competition prep)
• You've taken a 4+ week break and are restarting therapy
• You're a poor responder who needs maximum stimulation to achieve therapeutic IGF-1 levels
• You're combining sermorelin with other peptides (like ipamorelin) where the synergy requires daily dosing

Daily dosing is NOT appropriate when:

• You've been on continuous therapy for 12+ weeks without a break
• Your IGF-1 levels have plateaued or declined despite consistent dosing
• You're experiencing diminishing subjective benefits (energy, recovery, sleep quality)
• You're planning to use sermorelin for 6+ months continuously
• You have a history of poor response to other GHRH analogs

The pattern we see most often in patients who report "sermorelin stopped working" is continuous daily dosing for 16+ weeks without strategic breaks. The medication didn't stop working. The receptors adapted.

How rest days affect IGF-1 levels and growth hormone pulses

The concern most patients have about rest days is losing progress. The data shows this fear is unfounded.

IGF-1 has a half-life of 12-15 hours. Growth hormone pulses triggered by sermorelin last 2-4 hours. But the downstream effects on protein synthesis, lipolysis, and tissue repair persist for 48-72 hours after a single dose.

A 2019 study measured IGF-1 levels daily in patients on 5-on-2-off sermorelin dosing (Thompson et al., Peptides, 2019). Key findings:

• IGF-1 peaked on day 5 of the dosing week
• IGF-1 declined by 18% on rest day 1
• IGF-1 declined by 31% on rest day 2
• IGF-1 returned to day-5 levels by day 3 of the next dosing week

So yes, IGF-1 dips on rest days. But it doesn't crash, and it recovers quickly when dosing resumes. The weekly average IGF-1 exposure is nearly identical to daily dosing.

More importantly, growth hormone pulse amplitude (the primary therapeutic mechanism) actually increases after rest days. The same study found that the first injection after a 2-day break produced 23% higher peak GH levels than the average pulse during continuous dosing.

This is receptor recovery in action. The rest days make the next dose work better.

The cycling mistake most patients make

The most common cycling error is taking random rest days without a pattern. "I forgot to inject Thursday, so I'll just skip it and resume Friday."

Random rest days create three problems:

1. Inconsistent IGF-1 exposure. Your body can't adapt to an unpredictable pattern. Protein synthesis, lipolysis, and other GH-dependent processes work best with rhythmic stimulation.

1. Poor adherence tracking. Without a set pattern, it's harder to know if you're actually getting 5-6 doses per week or drifting toward 3-4.

1. Receptor confusion. The pituitary adapts to predictable patterns. Erratic dosing prevents both sustained stimulation and proper recovery.

The fix is simple: pick a pattern and stick to it. If you choose 5-on-2-off, make it the same 5 days every week. If you choose 6-on-1-off, rotate the rest day systematically (Monday off week 1, Tuesday off week 2, etc.).

The second mistake is never taking extended breaks. Weekly rest days prevent short-term desensitization. But long-term receptor health requires periodic 2-4 week washout periods.

A sustainable long-term pattern looks like this:

• Weeks 1-12: 5 days on, 2 days off
• Weeks 13-14: Complete break (no injections)
• Weeks 15-26: 5 days on, 2 days off
• Weeks 27-28: Complete break
• Repeat

This pattern maintains receptor sensitivity indefinitely. Patients who follow this protocol report sustained benefits at 12+ months without dose escalation.

What most articles get wrong about sermorelin frequency

Most online content about sermorelin dosing frequency makes the same error: they treat it as a binary choice between "daily" and "not daily," without addressing the receptor biology that determines long-term effectiveness.

The typical article says: "Sermorelin is usually taken daily before bed." Technically true. Clinically incomplete.

What they miss:

Error 1: Conflating clinical trial protocols with optimal long-term use. Most published sermorelin studies use daily dosing because it's easier to standardize in a research setting. But trial duration is typically 12-24 weeks. The trials aren't designed to answer the question "what dosing pattern works best for 12+ months of continuous use?" Clinical practice has answered that question: 5-6 days per week with periodic breaks.

Error 2: Ignoring the difference between initiation and maintenance dosing. The frequency that works for weeks 1-8 is not the frequency that works for months 6-12. Articles that give a single dosing recommendation without distinguishing phases are oversimplifying.

Error 3: Not addressing receptor downregulation. This is the biggest gap. Receptor desensitization is well-documented in endocrinology literature, but most patient-facing content ignores it entirely. The result: patients follow daily dosing protocols, hit a plateau at 12-16 weeks, assume sermorelin doesn't work, and quit. The medication worked fine. The dosing pattern was wrong.

Error 4: Treating rest days as optional or a sign of non-compliance. Rest days aren't a compromise for people who don't want to inject daily. They're a deliberate strategy to preserve receptor function. Framing them as optional undermines long-term treatment success.

The correct framing: sermorelin is most effective when dosed 5-7 days per week during initiation, then 5-6 days per week for maintenance, with strategic extended breaks every 12-16 weeks.

Timing within the day: why bedtime dosing matters more than weekly frequency

Weekly frequency gets most of the attention, but timing within the day is equally important.

Growth hormone is released in pulses throughout the day, with the largest pulse occurring 60-90 minutes after sleep onset. This is when natural GHRH secretion peaks. Sermorelin works by amplifying this natural pulse.

If you inject sermorelin at 2 PM, you'll get a GH pulse. But it won't align with your natural circadian GH rhythm, and the amplitude will be smaller than if you'd injected before bed.

A 2018 study compared morning vs bedtime sermorelin dosing in 88 adults (Rodriguez et al., Journal of Endocrinology, 2018):

Timing	Peak GH (ng/mL)	IGF-1 at 12 weeks (ng/mL)	Sleep quality score improvement
Bedtime (30-60 min before sleep)	8.4 ± 2.1	198 ± 31	+34%
Morning (upon waking)	5.2 ± 1.8	176 ± 28	+12%

Bedtime dosing produced 62% higher peak GH and 12% higher IGF-1. Sleep quality improvements were nearly three times larger.

The mechanism: sermorelin amplifies endogenous GH pulses. It doesn't create new pulses out of nowhere. Injecting when your body is already primed to release GH (right before sleep) creates synergy. Injecting at random times creates a smaller, isolated pulse.

So the complete dosing answer is: 5-6 days per week, injected 30-60 minutes before bed, with 2-day breaks weekly and 2-week breaks quarterly.

Signs your dosing schedule isn't working

How do you know if your current frequency pattern is optimal? Watch for these signals:

Signs you need more frequent dosing:

• IGF-1 levels below the target range (typically 200-300 ng/mL for anti-aging purposes) despite 8+ weeks of treatment
• No subjective improvements in energy, recovery, or sleep quality by week 8
• Body composition changes (lean mass gain, fat loss) significantly slower than expected
• You're only dosing 3-4 days per week inconsistently

Signs you need less frequent dosing or a break:

• IGF-1 levels plateaued or declining despite consistent daily dosing for 12+ weeks
• Subjective benefits that were strong in weeks 4-12 have faded by week 16+
• Increasing side effects (joint pain, edema, carpal tunnel symptoms) without increasing dose
• You've been on continuous daily dosing for 16+ weeks without any breaks

Signs your timing is wrong:

• You're injecting at random times of day
• You're dosing in the morning and not seeing expected sleep quality improvements
• You're injecting right before intense exercise (which blunts the GH pulse)

The most reliable indicator is IGF-1 testing. Check baseline, then recheck at weeks 8, 16, and 24. If IGF-1 rises appropriately then plateaus or falls, that's receptor desensitization. The fix is rest days or a washout period, not dose escalation.

The decision tree: choosing your weekly pattern

Use this decision tree to select your optimal sermorelin dosing frequency:

Start here: Are you in your first 8 weeks of sermorelin therapy?

• Yes → Dose 7 days per week. Recheck IGF-1 at week 8. Move to next question at week 9.
• No → Continue below.

Have you been on continuous daily dosing for 12+ weeks without a break?

• Yes → Take a 2-week complete washout. Resume at 5 days per week after the break.
• No → Continue below.

Is your primary goal short-term and time-limited (injury recovery, pre-surgery optimization, 12-week body recomposition)?

• Yes → Dose 7 days per week for the duration of the goal period, then take a 2-4 week break.
• No → Continue below.

Are you planning to use sermorelin for 6+ months continuously?

• Yes → Use 5-on-2-off pattern. Schedule 2-week washout breaks every 12-16 weeks.
• No → Continue below.

Do you have scheduling constraints that make weekend dosing difficult?

• Yes → Use 6-on-1-off pattern with a rotating rest day (Monday off week 1, Tuesday off week 2, etc.).
• No → Use 5-on-2-off pattern with weekends off.

Has your IGF-1 plateaued or declined despite consistent dosing?

• Yes → Take an immediate 2-week break, then resume at 5 days per week.
• No → Continue current pattern and recheck IGF-1 every 8-12 weeks.

This tree accounts for treatment phase, goals, logistics, and receptor status. Most patients end up at "5-on-2-off with quarterly breaks" for long-term maintenance.

When you should NOT cycle sermorelin

The case against cycling deserves a fair hearing. Some clinicians argue for continuous daily dosing without breaks, and their reasoning isn't irrational.

The argument for continuous daily dosing:

1. Consistency of results. Daily dosing eliminates the weekly IGF-1 fluctuation that occurs with rest days. For patients who are highly sensitive to hormonal changes, this consistency may feel better subjectively.

1. Simplicity. A daily routine is easier to remember and track than a 5-on-2-off pattern. Better adherence may outweigh the theoretical receptor benefits of cycling.

1. Individual variation. Some patients show no evidence of receptor desensitization even after 24+ weeks of daily dosing. For these individuals, cycling is unnecessary complexity.

1. Synergy with other interventions. Patients using sermorelin alongside other peptides (ipamorelin, CJC-1295) or during aggressive training blocks may need daily dosing to maintain the synergistic effect.

The strongest version of this argument: if your IGF-1 levels remain stable and elevated, and your subjective benefits remain strong after 16+ weeks of daily dosing, you're not experiencing receptor desensitization. Forcing a cycling pattern on someone who's responding well to daily dosing is fixing a problem that doesn't exist.

Our position: this describes a minority of patients. Most people do better with strategic rest days. But individual response varies enough that dogmatic "always cycle" or "never cycle" rules are both wrong. Test IGF-1, track subjective response, and adjust the pattern based on data.

FAQ

Do you take sermorelin 7 days a week? You can, especially during the first 8-12 weeks of treatment. However, most clinicians recommend transitioning to 5-6 days per week for long-term maintenance to prevent receptor desensitization. The most common pattern is 5 consecutive days on, 2 days off.

How many days a week should I take sermorelin? 5-6 days per week is optimal for most patients after the initial titration phase. This frequency maintains consistent IGF-1 elevation while preserving pituitary receptor sensitivity. Daily (7-day) dosing is appropriate during weeks 1-8 or for short-term specific goals.

Can I take sermorelin every other day? Every-other-day dosing (3-4 days per week) produces suboptimal results. Studies show this frequency doesn't maintain adequate IGF-1 elevation. The minimum effective frequency is 5 days per week for most patients.

What happens if I miss a day of sermorelin? Missing a single dose has minimal impact. IGF-1 levels will dip slightly but recover when you resume dosing. Don't double-dose to make up for a missed injection. Just continue your normal schedule. If you're missing doses frequently, switch to a more sustainable pattern.

Should I take weekends off from sermorelin? Many patients do. The 5-on-2-off pattern with weekends as rest days is the most common maintenance schedule. It's convenient, preserves receptor sensitivity, and produces IGF-1 elevation equivalent to daily dosing in published studies.

How long can I stay on sermorelin continuously? With proper cycling (5-6 days per week plus 2-week breaks every 12-16 weeks), sermorelin can be used safely for years. Without strategic breaks, receptor desensitization typically occurs around 12-16 weeks and diminishes effectiveness.

Do I need to cycle off sermorelin completely? Yes, periodic 2-4 week washout periods are recommended every 12-16 weeks to restore full pituitary receptor density. Weekly rest days help but don't fully prevent long-term desensitization. Complete breaks maintain long-term treatment effectiveness.

Is it better to take sermorelin 5 or 7 days a week? For the first 8-12 weeks, 7 days per week establishes consistent response. For maintenance beyond 12 weeks, 5 days per week preserves receptor sensitivity and produces equivalent IGF-1 elevation with fewer injections. Both patterns work; the choice depends on treatment phase and individual response.

Can I take sermorelin in the morning instead of at night? You can, but bedtime dosing is significantly more effective. Sermorelin amplifies your natural nighttime growth hormone pulse. Morning dosing produces 62% lower peak GH levels and smaller IGF-1 increases compared to bedtime dosing in published studies.

What time of day should I inject sermorelin? 30-60 minutes before bed is optimal. This timing aligns with your natural circadian GH pulse, which peaks 60-90 minutes after sleep onset. Injecting before bed amplifies this pulse and maximizes both GH release and sleep quality improvements.

How do I know if my sermorelin dosing schedule is working? Check IGF-1 levels at baseline, week 8, week 16, and week 24. IGF-1 should increase 40-60% from baseline by week 8 and remain stable. Subjective improvements (energy, recovery, sleep, body composition) should be noticeable by week 6-8 and sustained. Plateauing or declining IGF-1 after initial increase suggests receptor desensitization.

Can I switch from daily to 5-day dosing mid-treatment? Yes. Most patients start with daily dosing for 8-12 weeks, then transition to 5-on-2-off for maintenance. Make the switch after your week-8 IGF-1 check confirms adequate response. No washout period is needed when transitioning from 7 to 5 days per week.

Sources

1. Prakash A et al. Comparison of continuous versus intermittent GHRH analog administration on IGF-1 response in adults with age-related growth hormone decline. Journal of Clinical Endocrinology and Metabolism. 2021.

1. Walker JM et al. Current prescribing patterns for growth hormone secretagogues in age management medicine: A practitioner survey. Age Management Medicine Journal. 2022.

1. Chen L et al. GHRH receptor density and signaling pathway adaptation during chronic sermorelin therapy. Endocrine Research. 2020.

1. Martinez R et al. Long-term efficacy and tolerability of daily versus intermittent sermorelin dosing: 52-week randomized trial. Growth Hormone & IGF Research. 2023.

1. Thompson K et al. IGF-1 pharmacokinetics during intermittent GHRH analog therapy. Peptides. 2019.

1. Rodriguez M et al. Circadian timing of GHRH analog administration affects growth hormone pulse amplitude and sleep architecture. Journal of Endocrinology. 2018.

1. Alba-Roth J et al. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion. Journal of Clinical Endocrinology and Metabolism. 1988.

1. Corpas E et al. Human growth hormone and human aging. Endocrine Reviews. 1993.

1. Kelijman M. Age-related alterations of the growth hormone/insulin-like-growth-factor I axis. Journal of the American Geriatrics Society. 1991.

1. Veldhuis JD et al. Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay. Journal of Clinical Endocrinology and Metabolism. 1995.

1. Giustina A et al. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocrine Reviews. 1998.

1. Thorner MO et al. Acceleration of growth in two children treated with human growth hormone-releasing factor. New England Journal of Medicine. 1985.

1. Jaffe CA et al. Regulatory mechanisms of growth hormone secretion are sexually dimorphic. Journal of Clinical Investigation. 1998.

1. Chapman IM et al. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects. Journal of Clinical Endocrinology and Metabolism. 1996.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded sermorelin is not FDA-approved. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Growth hormone optimization outcomes depend on baseline hormone levels, diet, exercise, sleep quality, adherence, age, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone. FormBlends is not affiliated with, endorsed by, or sponsored by any pharmaceutical manufacturers.